Distal	B:C0205108
,	O
not	O
proximal	O
,	O
colonic	O
acetate	O
infusions	I:C0574032
promote	O
fat	O
oxidation	O
and	O
improve	O
metabolic	O
markers	I:C0578570
in	O
overweight	O
/	O
obese	O
men	O
.	O

Distal	O
,	O
not	O
proximal	B:C0205107
,	O
colonic	O
acetate	O
infusions	I:C0574032
promote	O
fat	O
oxidation	O
and	O
improve	O
metabolic	O
markers	I:C0578570
in	O
overweight	O
/	O
obese	O
men	O
.	O

Distal	O
,	O
not	O
proximal	O
,	O
colonic	B:C0009368
acetate	O
infusions	I:C0574032
promote	O
fat	O
oxidation	O
and	O
improve	O
metabolic	O
markers	I:C0578570
in	O
overweight	O
/	O
obese	O
men	O
.	O

Distal	O
,	O
not	O
proximal	O
,	O
colonic	O
acetate	B:C0574032
infusions	I:C0574032
promote	O
fat	O
oxidation	O
and	O
improve	O
metabolic	O
markers	I:C0578570
in	O
overweight	O
/	O
obese	O
men	O
.	O

Distal	O
,	O
not	O
proximal	O
,	O
colonic	O
acetate	O
infusions	I:C0574032
promote	O
fat	O
oxidation	O
and	O
improve	B:C0184511
metabolic	O
markers	I:C0578570
in	O
overweight	O
/	O
obese	O
men	O
.	O

Distal	O
,	O
not	O
proximal	O
,	O
colonic	O
acetate	O
infusions	I:C0574032
promote	O
fat	O
oxidation	O
and	O
improve	O
metabolic	B:C0578570
markers	I:C0578570
in	O
overweight	O
/	O
obese	O
men	O
.	O

Distal	O
,	O
not	O
proximal	O
,	O
colonic	O
acetate	O
infusions	I:C0574032
promote	O
fat	O
oxidation	O
and	O
improve	O
metabolic	O
markers	I:C0578570
in	O
overweight	B:C0497406
/	O
obese	O
men	O
.	O

Distal	O
,	O
not	O
proximal	O
,	O
colonic	O
acetate	O
infusions	I:C0574032
promote	O
fat	O
oxidation	O
and	O
improve	O
metabolic	O
markers	I:C0578570
in	O
overweight	O
/	O
obese	B:C0028754
men	O
.	O

Distal	O
,	O
not	O
proximal	O
,	O
colonic	O
acetate	O
infusions	I:C0574032
promote	O
fat	O
oxidation	O
and	O
improve	O
metabolic	O
markers	I:C0578570
in	O
overweight	O
/	O
obese	O
men	B:C0025266
.	O

Gut	O
microbial	O
-	O
derived	O
short	B:C0015691
-	I:C0015691
chain	I:C0015691
fatty	I:C0015691
acids	I:C0015691
(	O
short	O
-	I:C0015691
chain	I:C0015691
fatty	I:C0015691
acids	I:C0015691
)	O
are	O
believed	O
to	O
affect	O
host	O
metabolism	O
and	O
cardiometabolic	O
risk	I:C0035648
factors	I:C0035648
.	O

Gut	O
microbial	O
-	O
derived	O
short	O
-	I:C0015691
chain	I:C0015691
fatty	I:C0015691
acids	I:C0015691
(	O
short	B:C0015691
-	I:C0015691
chain	I:C0015691
fatty	I:C0015691
acids	I:C0015691
)	O
are	O
believed	O
to	O
affect	O
host	O
metabolism	O
and	O
cardiometabolic	O
risk	I:C0035648
factors	I:C0035648
.	O

Gut	O
microbial	O
-	O
derived	O
short	O
-	I:C0015691
chain	I:C0015691
fatty	I:C0015691
acids	I:C0015691
(	O
short	O
-	I:C0015691
chain	I:C0015691
fatty	I:C0015691
acids	I:C0015691
)	O
are	O
believed	O
to	O
affect	O
host	O
metabolism	B:C0025519
and	O
cardiometabolic	O
risk	I:C0035648
factors	I:C0035648
.	O

Gut	O
microbial	O
-	O
derived	O
short	O
-	I:C0015691
chain	I:C0015691
fatty	I:C0015691
acids	I:C0015691
(	O
short	O
-	I:C0015691
chain	I:C0015691
fatty	I:C0015691
acids	I:C0015691
)	O
are	O
believed	O
to	O
affect	O
host	O
metabolism	O
and	O
cardiometabolic	B:C0035648
risk	I:C0035648
factors	I:C0035648
.	O

The	O
present	O
study	O
aim	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
proximal	B:C0205107
and	O
distal	O
colonic	O
infusions	O
with	O
the	O
SCFA	O
acetate	I:C0015691
on	O
fat	O
oxidation	O
and	O
other	O
metabolic	O
parameters	O
in	O
men	O
.	O

The	O
present	O
study	O
aim	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
proximal	O
and	O
distal	B:C0205108
colonic	O
infusions	O
with	O
the	O
SCFA	O
acetate	I:C0015691
on	O
fat	O
oxidation	O
and	O
other	O
metabolic	O
parameters	O
in	O
men	O
.	O

The	O
present	O
study	O
aim	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
proximal	O
and	O
distal	O
colonic	B:C0009368
infusions	O
with	O
the	O
SCFA	O
acetate	I:C0015691
on	O
fat	O
oxidation	O
and	O
other	O
metabolic	O
parameters	O
in	O
men	O
.	O

The	O
present	O
study	O
aim	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
proximal	O
and	O
distal	O
colonic	O
infusions	B:C0574032
with	O
the	O
SCFA	O
acetate	I:C0015691
on	O
fat	O
oxidation	O
and	O
other	O
metabolic	O
parameters	O
in	O
men	O
.	O

The	O
present	O
study	O
aim	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
proximal	O
and	O
distal	O
colonic	O
infusions	O
with	O
the	O
SCFA	B:C0015691
acetate	I:C0015691
on	O
fat	O
oxidation	O
and	O
other	O
metabolic	O
parameters	O
in	O
men	O
.	O

The	O
present	O
study	O
aim	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
proximal	O
and	O
distal	O
colonic	O
infusions	O
with	O
the	O
SCFA	O
acetate	I:C0015691
on	O
fat	O
oxidation	O
and	O
other	O
metabolic	O
parameters	O
in	O
men	B:C0025266
.	O

In	O
this	O
randomized	B:C0034656
,	O
double	O
-	I:C0013072
blind	I:C0013072
crossover	O
trial	I:C0150097
,	O
six	O
overweight	O
/	O
obese	O
men	O
[	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
25	O
-	O
35	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
underwent	O
two	O
experimental	O
periods	O
:	O
one	O
with	O
distal	O
and	O
one	O
with	O
proximal	O
colonic	O
sodium	O
acetate	I:C2034525
infusions	I:C2034525
.	O

In	O
this	O
randomized	O
,	O
double	B:C0013072
-	I:C0013072
blind	I:C0013072
crossover	O
trial	I:C0150097
,	O
six	O
overweight	O
/	O
obese	O
men	O
[	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
25	O
-	O
35	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
underwent	O
two	O
experimental	O
periods	O
:	O
one	O
with	O
distal	O
and	O
one	O
with	O
proximal	O
colonic	O
sodium	O
acetate	I:C2034525
infusions	I:C2034525
.	O

In	O
this	O
randomized	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
crossover	B:C0150097
trial	I:C0150097
,	O
six	O
overweight	O
/	O
obese	O
men	O
[	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
25	O
-	O
35	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
underwent	O
two	O
experimental	O
periods	O
:	O
one	O
with	O
distal	O
and	O
one	O
with	O
proximal	O
colonic	O
sodium	O
acetate	I:C2034525
infusions	I:C2034525
.	O

In	O
this	O
randomized	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
crossover	O
trial	I:C0150097
,	O
six	O
overweight	B:C0497406
/	O
obese	O
men	O
[	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
25	O
-	O
35	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
underwent	O
two	O
experimental	O
periods	O
:	O
one	O
with	O
distal	O
and	O
one	O
with	O
proximal	O
colonic	O
sodium	O
acetate	I:C2034525
infusions	I:C2034525
.	O

In	O
this	O
randomized	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
crossover	O
trial	I:C0150097
,	O
six	O
overweight	O
/	O
obese	B:C0028754
men	O
[	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
25	O
-	O
35	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
underwent	O
two	O
experimental	O
periods	O
:	O
one	O
with	O
distal	O
and	O
one	O
with	O
proximal	O
colonic	O
sodium	O
acetate	I:C2034525
infusions	I:C2034525
.	O

In	O
this	O
randomized	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
crossover	O
trial	I:C0150097
,	O
six	O
overweight	O
/	O
obese	O
men	B:C0025266
[	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
25	O
-	O
35	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
underwent	O
two	O
experimental	O
periods	O
:	O
one	O
with	O
distal	O
and	O
one	O
with	O
proximal	O
colonic	O
sodium	O
acetate	I:C2034525
infusions	I:C2034525
.	O

In	O
this	O
randomized	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
crossover	O
trial	I:C0150097
,	O
six	O
overweight	O
/	O
obese	O
men	O
[	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
25	O
-	O
35	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
underwent	O
two	O
experimental	O
periods	O
:	O
one	O
with	O
distal	O
and	O
one	O
with	O
proximal	O
colonic	O
sodium	O
acetate	I:C2034525
infusions	I:C2034525
.	O

In	O
this	O
randomized	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
crossover	O
trial	I:C0150097
,	O
six	O
overweight	O
/	O
obese	O
men	O
[	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
)	O
25	O
-	O
35	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
underwent	O
two	O
experimental	O
periods	O
:	O
one	O
with	O
distal	O
and	O
one	O
with	O
proximal	O
colonic	O
sodium	O
acetate	I:C2034525
infusions	I:C2034525
.	O

In	O
this	O
randomized	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
crossover	O
trial	I:C0150097
,	O
six	O
overweight	O
/	O
obese	O
men	O
[	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
25	O
-	O
35	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
underwent	O
two	O
experimental	O
periods	O
:	O
one	O
with	O
distal	B:C0205108
and	O
one	O
with	O
proximal	O
colonic	O
sodium	O
acetate	I:C2034525
infusions	I:C2034525
.	O

In	O
this	O
randomized	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
crossover	O
trial	I:C0150097
,	O
six	O
overweight	O
/	O
obese	O
men	O
[	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
25	O
-	O
35	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
underwent	O
two	O
experimental	O
periods	O
:	O
one	O
with	O
distal	O
and	O
one	O
with	O
proximal	B:C0205107
colonic	O
sodium	O
acetate	I:C2034525
infusions	I:C2034525
.	O

In	O
this	O
randomized	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
crossover	O
trial	I:C0150097
,	O
six	O
overweight	O
/	O
obese	O
men	O
[	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
25	O
-	O
35	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
underwent	O
two	O
experimental	O
periods	O
:	O
one	O
with	O
distal	O
and	O
one	O
with	O
proximal	O
colonic	B:C0009368
sodium	O
acetate	I:C2034525
infusions	I:C2034525
.	O

In	O
this	O
randomized	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
crossover	O
trial	I:C0150097
,	O
six	O
overweight	O
/	O
obese	O
men	O
[	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
25	O
-	O
35	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
underwent	O
two	O
experimental	O
periods	O
:	O
one	O
with	O
distal	O
and	O
one	O
with	O
proximal	O
colonic	O
sodium	B:C2034525
acetate	I:C2034525
infusions	I:C2034525
.	O

A	O
feeding	B:C2945625
catheter	I:C2945625
was	O
endoscopically	O
positioned	O
at	O
the	O
beginning	O
of	O
each	O
period	O
and	O
remained	O
in	O
the	O
colon	O
for	O
three	O
consecutive	O
test	O
days	O
,	O
enabling	O
colonic	O
acetate	O
(	O
100	O
or	O
180	O
mmol	O
/	O
l	O
)	O
or	O
placebo	O
infusion	O
during	O
fasting	O
conditions	O
and	O
after	O
an	O
oral	O
glucose	I:C1955477
load	I:C1955477
(	O
postprandial	O
)	O
.	O

A	O
feeding	O
catheter	I:C2945625
was	O
endoscopically	B:C0442418
positioned	O
at	O
the	O
beginning	O
of	O
each	O
period	O
and	O
remained	O
in	O
the	O
colon	O
for	O
three	O
consecutive	O
test	O
days	O
,	O
enabling	O
colonic	O
acetate	O
(	O
100	O
or	O
180	O
mmol	O
/	O
l	O
)	O
or	O
placebo	O
infusion	O
during	O
fasting	O
conditions	O
and	O
after	O
an	O
oral	O
glucose	I:C1955477
load	I:C1955477
(	O
postprandial	O
)	O
.	O

A	O
feeding	O
catheter	I:C2945625
was	O
endoscopically	O
positioned	B:C0733755
at	O
the	O
beginning	O
of	O
each	O
period	O
and	O
remained	O
in	O
the	O
colon	O
for	O
three	O
consecutive	O
test	O
days	O
,	O
enabling	O
colonic	O
acetate	O
(	O
100	O
or	O
180	O
mmol	O
/	O
l	O
)	O
or	O
placebo	O
infusion	O
during	O
fasting	O
conditions	O
and	O
after	O
an	O
oral	O
glucose	I:C1955477
load	I:C1955477
(	O
postprandial	O
)	O
.	O

A	O
feeding	O
catheter	I:C2945625
was	O
endoscopically	O
positioned	O
at	O
the	O
beginning	O
of	O
each	O
period	O
and	O
remained	O
in	O
the	O
colon	B:C0009368
for	O
three	O
consecutive	O
test	O
days	O
,	O
enabling	O
colonic	O
acetate	O
(	O
100	O
or	O
180	O
mmol	O
/	O
l	O
)	O
or	O
placebo	O
infusion	O
during	O
fasting	O
conditions	O
and	O
after	O
an	O
oral	O
glucose	I:C1955477
load	I:C1955477
(	O
postprandial	O
)	O
.	O

A	O
feeding	O
catheter	I:C2945625
was	O
endoscopically	O
positioned	O
at	O
the	O
beginning	O
of	O
each	O
period	O
and	O
remained	O
in	O
the	O
colon	O
for	O
three	O
consecutive	O
test	O
days	O
,	O
enabling	O
colonic	B:C0009368
acetate	O
(	O
100	O
or	O
180	O
mmol	O
/	O
l	O
)	O
or	O
placebo	O
infusion	O
during	O
fasting	O
conditions	O
and	O
after	O
an	O
oral	O
glucose	I:C1955477
load	I:C1955477
(	O
postprandial	O
)	O
.	O

A	O
feeding	O
catheter	I:C2945625
was	O
endoscopically	O
positioned	O
at	O
the	O
beginning	O
of	O
each	O
period	O
and	O
remained	O
in	O
the	O
colon	O
for	O
three	O
consecutive	O
test	O
days	O
,	O
enabling	O
colonic	O
acetate	B:C0574032
(	O
100	O
or	O
180	O
mmol	O
/	O
l	O
)	O
or	O
placebo	O
infusion	O
during	O
fasting	O
conditions	O
and	O
after	O
an	O
oral	O
glucose	I:C1955477
load	I:C1955477
(	O
postprandial	O
)	O
.	O

A	O
feeding	O
catheter	I:C2945625
was	O
endoscopically	O
positioned	O
at	O
the	O
beginning	O
of	O
each	O
period	O
and	O
remained	O
in	O
the	O
colon	O
for	O
three	O
consecutive	O
test	O
days	O
,	O
enabling	O
colonic	O
acetate	O
(	O
100	O
or	O
180	O
mmol	O
/	O
l	O
)	O
or	O
placebo	B:C1696465
infusion	O
during	O
fasting	O
conditions	O
and	O
after	O
an	O
oral	O
glucose	I:C1955477
load	I:C1955477
(	O
postprandial	O
)	O
.	O

A	O
feeding	O
catheter	I:C2945625
was	O
endoscopically	O
positioned	O
at	O
the	O
beginning	O
of	O
each	O
period	O
and	O
remained	O
in	O
the	O
colon	O
for	O
three	O
consecutive	O
test	O
days	O
,	O
enabling	O
colonic	O
acetate	O
(	O
100	O
or	O
180	O
mmol	O
/	O
l	O
)	O
or	O
placebo	O
infusion	B:C0574032
during	O
fasting	O
conditions	O
and	O
after	O
an	O
oral	O
glucose	I:C1955477
load	I:C1955477
(	O
postprandial	O
)	O
.	O

A	O
feeding	O
catheter	I:C2945625
was	O
endoscopically	O
positioned	O
at	O
the	O
beginning	O
of	O
each	O
period	O
and	O
remained	O
in	O
the	O
colon	O
for	O
three	O
consecutive	O
test	O
days	O
,	O
enabling	O
colonic	O
acetate	O
(	O
100	O
or	O
180	O
mmol	O
/	O
l	O
)	O
or	O
placebo	O
infusion	O
during	O
fasting	B:C0015663
conditions	O
and	O
after	O
an	O
oral	O
glucose	I:C1955477
load	I:C1955477
(	O
postprandial	O
)	O
.	O

A	O
feeding	O
catheter	I:C2945625
was	O
endoscopically	O
positioned	O
at	O
the	O
beginning	O
of	O
each	O
period	O
and	O
remained	O
in	O
the	O
colon	O
for	O
three	O
consecutive	O
test	O
days	O
,	O
enabling	O
colonic	O
acetate	O
(	O
100	O
or	O
180	O
mmol	O
/	O
l	O
)	O
or	O
placebo	O
infusion	O
during	O
fasting	O
conditions	O
and	O
after	O
an	O
oral	B:C1955477
glucose	I:C1955477
load	I:C1955477
(	O
postprandial	O
)	O
.	O

Fat	O
oxidation	O
and	O
energy	B:C0014272
expenditure	I:C0014272
were	O
measured	O
using	O
an	O
open	O
-	I:C0025080
circuit	I:C0025080
ventilated	I:C0025080
hood	I:C0025080
system	I:C0025080
and	O
blood	O
samples	I:C0178913
were	O
repeatedly	O
collected	O
for	O
2	O
h	O
during	O
fasting	O
and	O
postprandial	O
conditions	O
.	O

Fat	O
oxidation	O
and	O
energy	O
expenditure	I:C0014272
were	O
measured	O
using	O
an	O
open	B:C0025080
-	I:C0025080
circuit	I:C0025080
ventilated	I:C0025080
hood	I:C0025080
system	I:C0025080
and	O
blood	O
samples	I:C0178913
were	O
repeatedly	O
collected	O
for	O
2	O
h	O
during	O
fasting	O
and	O
postprandial	O
conditions	O
.	O

Fat	O
oxidation	O
and	O
energy	O
expenditure	I:C0014272
were	O
measured	O
using	O
an	O
open	O
-	I:C0025080
circuit	I:C0025080
ventilated	I:C0025080
hood	I:C0025080
system	I:C0025080
and	O
blood	B:C0178913
samples	I:C0178913
were	O
repeatedly	O
collected	O
for	O
2	O
h	O
during	O
fasting	O
and	O
postprandial	O
conditions	O
.	O

Fat	O
oxidation	O
and	O
energy	O
expenditure	I:C0014272
were	O
measured	O
using	O
an	O
open	O
-	I:C0025080
circuit	I:C0025080
ventilated	I:C0025080
hood	I:C0025080
system	I:C0025080
and	O
blood	O
samples	I:C0178913
were	O
repeatedly	O
collected	O
for	O
2	O
h	O
during	O
fasting	B:C0015663
and	O
postprandial	O
conditions	O
.	O

Distal	B:C0205108
colonic	O
180	O
mmol	O
/	O
l	O
acetate	O
infusions	I:C0574032
increased	O
fasting	O
fat	O
oxidation	O
(	O
1.78±0.28	O
compared	O
with	O
-	O
0.78±0.89	O
g	O
fat	O
2	O
h(	O
-	O
1	O
)	O
,	O
P=0.015	O
)	O
,	O
fasting	O
peptide	O
YY	I:C0070358
(	O
peptide	O
YY	I:C0070358
,	O
P=0.01	O
)	O
and	O
postprandial	O
glucose	O
and	O
insulin	O
concentrations	O
(	O
P<	O
0.05	O
)	O
,	O
and	O
tended	O
to	O
increase	O
fasting	O
plasma	O
acetate	O
(	O
P=0.069	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
colonic	B:C0009368
180	O
mmol	O
/	O
l	O
acetate	O
infusions	I:C0574032
increased	O
fasting	O
fat	O
oxidation	O
(	O
1.78±0.28	O
compared	O
with	O
-	O
0.78±0.89	O
g	O
fat	O
2	O
h(	O
-	O
1	O
)	O
,	O
P=0.015	O
)	O
,	O
fasting	O
peptide	O
YY	I:C0070358
(	O
peptide	O
YY	I:C0070358
,	O
P=0.01	O
)	O
and	O
postprandial	O
glucose	O
and	O
insulin	O
concentrations	O
(	O
P<	O
0.05	O
)	O
,	O
and	O
tended	O
to	O
increase	O
fasting	O
plasma	O
acetate	O
(	O
P=0.069	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
colonic	O
180	O
mmol	O
/	O
l	O
acetate	B:C0574032
infusions	I:C0574032
increased	O
fasting	O
fat	O
oxidation	O
(	O
1.78±0.28	O
compared	O
with	O
-	O
0.78±0.89	O
g	O
fat	O
2	O
h(	O
-	O
1	O
)	O
,	O
P=0.015	O
)	O
,	O
fasting	O
peptide	O
YY	I:C0070358
(	O
peptide	O
YY	I:C0070358
,	O
P=0.01	O
)	O
and	O
postprandial	O
glucose	O
and	O
insulin	O
concentrations	O
(	O
P<	O
0.05	O
)	O
,	O
and	O
tended	O
to	O
increase	O
fasting	O
plasma	O
acetate	O
(	O
P=0.069	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
colonic	O
180	O
mmol	O
/	O
l	O
acetate	O
infusions	I:C0574032
increased	O
fasting	B:C0015663
fat	O
oxidation	O
(	O
1.78±0.28	O
compared	O
with	O
-	O
0.78±0.89	O
g	O
fat	O
2	O
h(	O
-	O
1	O
)	O
,	O
P=0.015	O
)	O
,	O
fasting	O
peptide	O
YY	I:C0070358
(	O
peptide	O
YY	I:C0070358
,	O
P=0.01	O
)	O
and	O
postprandial	O
glucose	O
and	O
insulin	O
concentrations	O
(	O
P<	O
0.05	O
)	O
,	O
and	O
tended	O
to	O
increase	O
fasting	O
plasma	O
acetate	O
(	O
P=0.069	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
colonic	O
180	O
mmol	O
/	O
l	O
acetate	O
infusions	I:C0574032
increased	O
fasting	O
fat	O
oxidation	O
(	O
1.78±0.28	O
compared	O
with	O
-	O
0.78±0.89	O
g	O
fat	O
2	O
h(	O
-	O
1	O
)	O
,	O
P=0.015	O
)	O
,	O
fasting	B:C0015663
peptide	O
YY	I:C0070358
(	O
peptide	O
YY	I:C0070358
,	O
P=0.01	O
)	O
and	O
postprandial	O
glucose	O
and	O
insulin	O
concentrations	O
(	O
P<	O
0.05	O
)	O
,	O
and	O
tended	O
to	O
increase	O
fasting	O
plasma	O
acetate	O
(	O
P=0.069	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
colonic	O
180	O
mmol	O
/	O
l	O
acetate	O
infusions	I:C0574032
increased	O
fasting	O
fat	O
oxidation	O
(	O
1.78±0.28	O
compared	O
with	O
-	O
0.78±0.89	O
g	O
fat	O
2	O
h(	O
-	O
1	O
)	O
,	O
P=0.015	O
)	O
,	O
fasting	O
peptide	B:C0070358
YY	I:C0070358
(	O
peptide	O
YY	I:C0070358
,	O
P=0.01	O
)	O
and	O
postprandial	O
glucose	O
and	O
insulin	O
concentrations	O
(	O
P<	O
0.05	O
)	O
,	O
and	O
tended	O
to	O
increase	O
fasting	O
plasma	O
acetate	O
(	O
P=0.069	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
colonic	O
180	O
mmol	O
/	O
l	O
acetate	O
infusions	I:C0574032
increased	O
fasting	O
fat	O
oxidation	O
(	O
1.78±0.28	O
compared	O
with	O
-	O
0.78±0.89	O
g	O
fat	O
2	O
h(	O
-	O
1	O
)	O
,	O
P=0.015	O
)	O
,	O
fasting	O
peptide	O
YY	I:C0070358
(	O
peptide	B:C0070358
YY	I:C0070358
,	O
P=0.01	O
)	O
and	O
postprandial	O
glucose	O
and	O
insulin	O
concentrations	O
(	O
P<	O
0.05	O
)	O
,	O
and	O
tended	O
to	O
increase	O
fasting	O
plasma	O
acetate	O
(	O
P=0.069	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
colonic	O
180	O
mmol	O
/	O
l	O
acetate	O
infusions	I:C0574032
increased	O
fasting	O
fat	O
oxidation	O
(	O
1.78±0.28	O
compared	O
with	O
-	O
0.78±0.89	O
g	O
fat	O
2	O
h(	O
-	O
1	O
)	O
,	O
P=0.015	O
)	O
,	O
fasting	O
peptide	O
YY	I:C0070358
(	O
peptide	O
YY	I:C0070358
,	O
P=0.01	O
)	O
and	O
postprandial	O
glucose	B:C0017725
and	O
insulin	O
concentrations	O
(	O
P<	O
0.05	O
)	O
,	O
and	O
tended	O
to	O
increase	O
fasting	O
plasma	O
acetate	O
(	O
P=0.069	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
colonic	O
180	O
mmol	O
/	O
l	O
acetate	O
infusions	I:C0574032
increased	O
fasting	O
fat	O
oxidation	O
(	O
1.78±0.28	O
compared	O
with	O
-	O
0.78±0.89	O
g	O
fat	O
2	O
h(	O
-	O
1	O
)	O
,	O
P=0.015	O
)	O
,	O
fasting	O
peptide	O
YY	I:C0070358
(	O
peptide	O
YY	I:C0070358
,	O
P=0.01	O
)	O
and	O
postprandial	O
glucose	O
and	O
insulin	B:C0021641
concentrations	O
(	O
P<	O
0.05	O
)	O
,	O
and	O
tended	O
to	O
increase	O
fasting	O
plasma	O
acetate	O
(	O
P=0.069	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
colonic	O
180	O
mmol	O
/	O
l	O
acetate	O
infusions	I:C0574032
increased	O
fasting	O
fat	O
oxidation	O
(	O
1.78±0.28	O
compared	O
with	O
-	O
0.78±0.89	O
g	O
fat	O
2	O
h(	O
-	O
1	O
)	O
,	O
P=0.015	O
)	O
,	O
fasting	O
peptide	O
YY	I:C0070358
(	O
peptide	O
YY	I:C0070358
,	O
P=0.01	O
)	O
and	O
postprandial	O
glucose	O
and	O
insulin	O
concentrations	O
(	O
P<	O
0.05	O
)	O
,	O
and	O
tended	O
to	O
increase	O
fasting	B:C0015663
plasma	O
acetate	O
(	O
P=0.069	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
colonic	O
180	O
mmol	O
/	O
l	O
acetate	O
infusions	I:C0574032
increased	O
fasting	O
fat	O
oxidation	O
(	O
1.78±0.28	O
compared	O
with	O
-	O
0.78±0.89	O
g	O
fat	O
2	O
h(	O
-	O
1	O
)	O
,	O
P=0.015	O
)	O
,	O
fasting	O
peptide	O
YY	I:C0070358
(	O
peptide	O
YY	I:C0070358
,	O
P=0.01	O
)	O
and	O
postprandial	O
glucose	O
and	O
insulin	O
concentrations	O
(	O
P<	O
0.05	O
)	O
,	O
and	O
tended	O
to	O
increase	O
fasting	O
plasma	B:C0032105
acetate	O
(	O
P=0.069	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
colonic	O
180	O
mmol	O
/	O
l	O
acetate	O
infusions	I:C0574032
increased	O
fasting	O
fat	O
oxidation	O
(	O
1.78±0.28	O
compared	O
with	O
-	O
0.78±0.89	O
g	O
fat	O
2	O
h(	O
-	O
1	O
)	O
,	O
P=0.015	O
)	O
,	O
fasting	O
peptide	O
YY	I:C0070358
(	O
peptide	O
YY	I:C0070358
,	O
P=0.01	O
)	O
and	O
postprandial	O
glucose	O
and	O
insulin	O
concentrations	O
(	O
P<	O
0.05	O
)	O
,	O
and	O
tended	O
to	O
increase	O
fasting	O
plasma	O
acetate	B:C0000975
(	O
P=0.069	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
colonic	O
180	O
mmol	O
/	O
l	O
acetate	O
infusions	I:C0574032
increased	O
fasting	O
fat	O
oxidation	O
(	O
1.78±0.28	O
compared	O
with	O
-	O
0.78±0.89	O
g	O
fat	O
2	O
h(	O
-	O
1	O
)	O
,	O
P=0.015	O
)	O
,	O
fasting	O
peptide	O
YY	I:C0070358
(	O
peptide	O
YY	I:C0070358
,	O
P=0.01	O
)	O
and	O
postprandial	O
glucose	O
and	O
insulin	O
concentrations	O
(	O
P<	O
0.05	O
)	O
,	O
and	O
tended	O
to	O
increase	O
fasting	O
plasma	O
acetate	O
(	O
P=0.069	O
)	O
compared	O
with	O
placebo	B:C1696465
.	O

Distal	B:C0205108
100	O
mmol	O
/	O
l	O
acetate	O
administration	I:C0574032
tended	O
to	O
decrease	O
fasting	O
tumour	O
necrosis	I:C1456820
factor	I:C1456820
-α	I:C1456820
(	O
tumour	O
necrosis	I:C1456820
factor	I:C1456820
-	I:C1456820
α	I:C1456820
;	O
P=0.067	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
100	O
mmol	O
/	O
l	O
acetate	B:C0574032
administration	I:C0574032
tended	O
to	O
decrease	O
fasting	O
tumour	O
necrosis	I:C1456820
factor	I:C1456820
-α	I:C1456820
(	O
tumour	O
necrosis	I:C1456820
factor	I:C1456820
-	I:C1456820
α	I:C1456820
;	O
P=0.067	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
100	O
mmol	O
/	O
l	O
acetate	O
administration	I:C0574032
tended	O
to	O
decrease	O
fasting	B:C0015663
tumour	O
necrosis	I:C1456820
factor	I:C1456820
-α	I:C1456820
(	O
tumour	O
necrosis	I:C1456820
factor	I:C1456820
-	I:C1456820
α	I:C1456820
;	O
P=0.067	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
100	O
mmol	O
/	O
l	O
acetate	O
administration	I:C0574032
tended	O
to	O
decrease	O
fasting	O
tumour	B:C1456820
necrosis	I:C1456820
factor	I:C1456820
-α	I:C1456820
(	O
tumour	O
necrosis	I:C1456820
factor	I:C1456820
-	I:C1456820
α	I:C1456820
;	O
P=0.067	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
100	O
mmol	O
/	O
l	O
acetate	O
administration	I:C0574032
tended	O
to	O
decrease	O
fasting	O
tumour	O
necrosis	I:C1456820
factor	I:C1456820
-α	I:C1456820
(	O
tumour	B:C1456820
necrosis	I:C1456820
factor	I:C1456820
-	I:C1456820
α	I:C1456820
;	O
P=0.067	O
)	O
compared	O
with	O
placebo	O
.	O

Distal	O
100	O
mmol	O
/	O
l	O
acetate	O
administration	I:C0574032
tended	O
to	O
decrease	O
fasting	O
tumour	O
necrosis	I:C1456820
factor	I:C1456820
-α	I:C1456820
(	O
tumour	O
necrosis	I:C1456820
factor	I:C1456820
-	I:C1456820
α	I:C1456820
;	O
P=0.067	O
)	O
compared	O
with	O
placebo	B:C1696465
.	O

In	O
contrast	O
,	O
proximal	B:C0205107
colonic	O
acetate	O
infusions	I:C0574032
showed	O
no	O
effects	O
on	O
substrate	O
metabolism	O
,	O
circulating	O
hormones	O
or	O
inflammatory	O
markers	O
.	O

In	O
contrast	O
,	O
proximal	O
colonic	B:C0009368
acetate	O
infusions	I:C0574032
showed	O
no	O
effects	O
on	O
substrate	O
metabolism	O
,	O
circulating	O
hormones	O
or	O
inflammatory	O
markers	O
.	O

In	O
contrast	O
,	O
proximal	O
colonic	O
acetate	B:C0574032
infusions	I:C0574032
showed	O
no	O
effects	O
on	O
substrate	O
metabolism	O
,	O
circulating	O
hormones	O
or	O
inflammatory	O
markers	O
.	O

In	O
contrast	O
,	O
proximal	O
colonic	O
acetate	O
infusions	I:C0574032
showed	O
no	O
effects	O
on	O
substrate	O
metabolism	B:C0025519
,	O
circulating	O
hormones	O
or	O
inflammatory	O
markers	O
.	O

In	O
contrast	O
,	O
proximal	O
colonic	O
acetate	O
infusions	I:C0574032
showed	O
no	O
effects	O
on	O
substrate	O
metabolism	O
,	O
circulating	O
hormones	B:C0019932
or	O
inflammatory	O
markers	O
.	O

In	O
contrast	O
,	O
proximal	O
colonic	O
acetate	O
infusions	I:C0574032
showed	O
no	O
effects	O
on	O
substrate	O
metabolism	O
,	O
circulating	O
hormones	O
or	O
inflammatory	O
markers	B:C0005516
.	O

In	O
conclusion	O
distal	B:C0205108
colonic	O
acetate	O
infusions	I:C0574032
affected	O
whole	O
-	I:C0444584
body	I:C0444584
substrate	O
metabolism	O
,	O
with	O
a	O
pronounced	O
increase	O
in	O
fasting	O
fat	O
oxidation	O
and	O
plasma	O
peptide	O
YY	I:C0070358
.	O

In	O
conclusion	O
distal	O
colonic	B:C0009368
acetate	O
infusions	I:C0574032
affected	O
whole	O
-	I:C0444584
body	I:C0444584
substrate	O
metabolism	O
,	O
with	O
a	O
pronounced	O
increase	O
in	O
fasting	O
fat	O
oxidation	O
and	O
plasma	O
peptide	O
YY	I:C0070358
.	O

In	O
conclusion	O
distal	O
colonic	O
acetate	B:C0574032
infusions	I:C0574032
affected	O
whole	O
-	I:C0444584
body	I:C0444584
substrate	O
metabolism	O
,	O
with	O
a	O
pronounced	O
increase	O
in	O
fasting	O
fat	O
oxidation	O
and	O
plasma	O
peptide	O
YY	I:C0070358
.	O

In	O
conclusion	O
distal	O
colonic	O
acetate	O
infusions	I:C0574032
affected	O
whole	B:C0444584
-	I:C0444584
body	I:C0444584
substrate	O
metabolism	O
,	O
with	O
a	O
pronounced	O
increase	O
in	O
fasting	O
fat	O
oxidation	O
and	O
plasma	O
peptide	O
YY	I:C0070358
.	O

In	O
conclusion	O
distal	O
colonic	O
acetate	O
infusions	I:C0574032
affected	O
whole	O
-	I:C0444584
body	I:C0444584
substrate	O
metabolism	B:C0025519
,	O
with	O
a	O
pronounced	O
increase	O
in	O
fasting	O
fat	O
oxidation	O
and	O
plasma	O
peptide	O
YY	I:C0070358
.	O

In	O
conclusion	O
distal	O
colonic	O
acetate	O
infusions	I:C0574032
affected	O
whole	O
-	I:C0444584
body	I:C0444584
substrate	O
metabolism	O
,	O
with	O
a	O
pronounced	O
increase	O
in	O
fasting	B:C0015663
fat	O
oxidation	O
and	O
plasma	O
peptide	O
YY	I:C0070358
.	O

In	O
conclusion	O
distal	O
colonic	O
acetate	O
infusions	I:C0574032
affected	O
whole	O
-	I:C0444584
body	I:C0444584
substrate	O
metabolism	O
,	O
with	O
a	O
pronounced	O
increase	O
in	O
fasting	O
fat	O
oxidation	O
and	O
plasma	B:C0032105
peptide	O
YY	I:C0070358
.	O

In	O
conclusion	O
distal	O
colonic	O
acetate	O
infusions	I:C0574032
affected	O
whole	O
-	I:C0444584
body	I:C0444584
substrate	O
metabolism	O
,	O
with	O
a	O
pronounced	O
increase	O
in	O
fasting	O
fat	O
oxidation	O
and	O
plasma	O
peptide	B:C0070358
YY	I:C0070358
.	O

Modulating	B:C0443264
colonic	O
acetate	O
may	O
be	O
a	O
nutritional	O
target	O
to	O
treat	O
or	O
prevent	O
metabolic	O
disorders	I:C0025517
.	O

Modulating	O
colonic	B:C0009368
acetate	O
may	O
be	O
a	O
nutritional	O
target	O
to	O
treat	O
or	O
prevent	O
metabolic	O
disorders	I:C0025517
.	O

Modulating	O
colonic	O
acetate	B:C0000975
may	O
be	O
a	O
nutritional	O
target	O
to	O
treat	O
or	O
prevent	O
metabolic	O
disorders	I:C0025517
.	O

Modulating	O
colonic	O
acetate	O
may	O
be	O
a	O
nutritional	O
target	O
to	O
treat	B:C0087111
or	O
prevent	O
metabolic	O
disorders	I:C0025517
.	O

Modulating	O
colonic	O
acetate	O
may	O
be	O
a	O
nutritional	O
target	O
to	O
treat	O
or	O
prevent	O
metabolic	B:C0025517
disorders	I:C0025517
.	O

